Previously, we and others have demonstrated the efficacy of BET inhibitors in triple-negative breast cancer (TNBC), an aggressive subtype of breast cancer that lacks targeted therapies11,12. The gene discussed is DNER; the disease is triple-negative breast carcinoma.